NCT04025216: A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

NCT04025216
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: MUC1
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have MUC1-Tn+ tumor; Patients must have disease progression following at least 1 prior systemic anti-cancer therapy regimen
Exclusions: 
https://ClinicalTrials.gov/show/NCT04025216

Comments are closed.

Up ↑